In a report released today, Robert LeBoyer from Noble Financial maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a price target of $6.00. The company’s shares closed last Friday at $1.52.
According to TipRanks, LeBoyer is an analyst with an average return of -10.2% and a 24.88% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as GeoVax Labs, Unicycive Therapeutics, and Onconova Therapeutics.
Unicycive Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $4.83, which is a 217.76% upside from current levels. In a report released on March 5, H.C. Wainwright also maintained a Buy rating on the stock with a $4.50 price target.
See Insiders’ Hot Stocks on TipRanks >>
UNCY market cap is currently $52.83M and has a P/E ratio of -0.88.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Unicycive Therapeutics (UNCY) Company Description:
Unicycive Therapeutics Inc is a biotechnology company dedicated towards developing treatments for certain medical conditions. It is focusing on kidney diseases. The company’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive’s other drug, UNI-494, is a new chemical entity with issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
Read More on UNCY:
- Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
- Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
- Unicycive Therapeutics receives Orphan Drug Designation for UNI-494
- Unicycive Therapeutics’ prevention of delayed graft function gets orphan status
- Unicycive prevention of delayed graft function treatment granted orphan status
